Table 2.
Risk Factors for Readmission
| Author (Year) | Age | Male | DM | HTN | IHD | CKD | AF | COPD | EF | HF Type | Beta- Blockers | ACEI/ARB | AA | Diuretics | Digoxin | LOS | 30-Day Readmission/ Total Patients | 1-Year Readmission/ Total Patients |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aizawa H 201518 | 36,313 (53.2) | 26,825 (39.3) | 38,292 (56.1) | 23,890 (35) | 53,309 (78.1) | 7850 (11.5) | 19 (Median) | 4479/68,257 (6.56) | ||||||||||
| Babayan ZY 200333 | 236 (47.87) | 199 (40.37) | 344 (69.78) | 96 (19.47) | 166 (33.67) | 279/493 (56.6) | ||||||||||||
| Bradford C 201619 | 72 | 1331 (55) | 721 (29.8) | 56 (2.3) | 1087 (44.9) | 1031 (42.6) | 394/2420 (16.28) | |||||||||||
| Corrao G 201520 | 79.3 (9.5) | 6103 (46.3) | CAD 2081 (15.8) | 886 (6.7) | 2441 (18.5) | RD 2459 (18.7) | 5537 (42) | 8739 (66.4) | 1163 (8.8) | 6334 (48.1) | 12.0 (10.3) | 566/13,171 (4.3) | 7534/13,171 (57.2) | |||||
| Dai S 201621 | 173 (72.1) | 129 (53.75) | 194 (80.83) | 165 (68.75) | 54 (22.5) | ≤40% | Decompensated HF | 233 (97.08) | 135 (56.25) | 121 (50.4) | 208 (86.6) | 48/240 (20) | ||||||
| Fernandez-Gasso L 201722 | 76.9 | 10,601 (43) | 814 (3.3) | 3156 (12.8) | 4938/24,654 (20) | |||||||||||||
| Golas SB 201823 | 75.7 | 6073 (52.8) | 2470 (21.46) | 4293 (37.3) | 3004 (26.1) | 4949 (43) | 4259 (37) | 6909 (60) | 3502/11,510 (30.4) | |||||||||
| Harikrishnan S 201740 | 61.2 (13.7) | 831 (69) | 662 (54.94) | 696 (57.76) | 866 (71.87) | 216 (17.93) | 177 (14.69) | 186 (15.44) | 333/1205 (30.2) | |||||||||
| Leong KT 200741 | 68.7 | 89 (51.4) | 87 (50.3) | 117 (67.6) | 81 (46.8) | 29 (16.5) | 72 (41.6) | 130 (75.1) | 63 (36.4) | 155 (89.6) | 33 (19.1) | 84/173 (48.55) | ||||||
| Mavrea AM 201542 | 64.6 | 98 (55) | 57 (32.02) | 136 (76.4) | CAD 108 (60.67) | CKD 87 (48.88) | 70 (39.33) | 44 (24.72) | HFpEF | 152 (85.39) | 129 (72.4) | 129 (72.4) | 116/178 (65.17) | |||||
| McLaren DP 201624 | 68.2 (15.6) | 1175 (59) | 714 (36) | 718 (36) | 784 (39) | 7.9 ± 15.2 | 366/1999 (18) | |||||||||||
| Reynolds K 201544 | 73.9 | 10,541 (52.9) | 9326 (46.8) | 17,077 (85.7) | CAD 9047 (45.4) | CKD 12415 (62.3) | 10,003 (50.2) | 9206 (46.2) | 9386 (47.1) | 2013 (10.1) | 11,956/19,927 (60) | |||||||
| Sterling MR 201825 | 60 | 477 (54) | 377 (44) | CAD 375 (43) | COPD 242 (27.4) | 40 (15, 60) | 210/883 (23.8) | |||||||||||
| Tuppin P 201326 | 78 | 33,580 (48) | 13,852 (19.8) | 6996 (1) | CAD 10704 (15.3) | 27,703 (39.6) | 39,176 (56) | 41,835(59.8) | 9 | 12,592/69,958 (18) | ||||||||
| Whittaker BD 201427 | 59 (17) | 148 (61.9) | 88 (36.8) | 117 (49) | CHD 90 (37.7) | 119 (49.8) | COPD 43 (18.0) | 119 (49.8) | 9.7 ± 14.9 | 50/239 (20.9) | ||||||||
| Wiley JF 201728 | 73 (13) | 540 (65) | 510 (61) | 590 (71) | CAD 494 (60) | RD 409 (49) | CHF | 216/830 (26) |
Abbreviations: DM, Diabetes Mellitus; HTN, Hypertension; IHD, Ischemic Heart Disease; CKD, Chronic Kidney Disease; AF, Atrial Fibrillation; COPD, Chronic Obstructive Pulmonary Disease; EF, Ejection Fraction; HF, Heart Failure; ACEI/ARB, Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers; AA, Aldosterone Antagonist; LOS, Length Of Stay; CAD, Coronary Artery Disease; RD, Respiratory Disease; HFpEF, Heart Failure with preserved Ejection Fraction; CHD, Coronary Heart Disease; CHF, Chronic Heart Failure.